Hospira irinotecan hydrochloride trihydrate IV Infusion 100 mg Australia - English - Department of Health (Therapeutic Goods Administration)

hospira irinotecan hydrochloride trihydrate iv infusion 100 mg

hospira australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; sorbitol; water for injections - small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, ovarian cancer, stomach cancer (inoperable or recurrent), colorectal cancer (inoperable or recurrent), breast cancer (inoperable or recurrent), squamous cell carcinoma, malignant lymphoma (non hodgkin's disease).

Hospira irinotecan hydrochloride trihydrate IV Infusion 40 mg Australia - English - Department of Health (Therapeutic Goods Administration)

hospira irinotecan hydrochloride trihydrate iv infusion 40 mg

hospira australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; sorbitol; water for injections - small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, ovarian cancer, stomach cancer (inoperable or recurrent), colorectal cancer (inoperable or recurrent), breast cancer (inoperable or recurrent), squamous cell carcinoma, malignant lymphoma (non hodgkin's disease).

Hospira Gemcitabine for IV Infusion 1 g Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine for iv infusion 1 g

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium acetate trihydrate - non-small cell lung cancer, pancreatic cancer, biliary tract cancer, uroepithelial cancer, inoperable or recurrent breast cancer, ovarian cancer progressing after chemotherapy.

Hospira Gemcitabine for IV Infusion 200 mg Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine for iv infusion 200 mg

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium acetate trihydrate - non-small cell lung cancer, pancreatic cancer, biliary tract cancer, uroepithelial cancer, inoperable or recurrent breast cancer, ovarian cancer progressing after chemotherapy.

Hospira Tomudex powder for solution for infusion 2 mg/vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira tomudex powder for solution for infusion 2 mg/vial

hospira australia pty ltd - raltitrexed, quantity: 2 mg - injection, powder for - excipient ingredients: mannitol; dibasic sodium phosphate dodecahydrate - pallative treatment of advanced colorectal cancer where 5-flourouracil and folinic acid based regimens are either not tolerated or inappropriate.

Hospira Gemcitabine Injection (38 mg/mL) 200 mg/5.26 mL (US) Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine injection (38 mg/ml) 200 mg/5.26 ml (us)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml; water for injections - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid - ovarian cancer, breast cancer, non small cell lung cancer, pancreatic cancer

Hospira Gemcitabine Injection (38 mg/mL) 1 g/26.3 mL (US) Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine injection (38 mg/ml) 1 g/26.3 ml (us)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - ovarian cancer, breast cancer, non small cell lung cancer, pancreatic cancer

Hospira Gemcitabine Injection (38 mg/mL) 2 g/52.6 mL (US) Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine injection (38 mg/ml) 2 g/52.6 ml (us)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - ovarian cancer, breast cancer, non small cell lung cancer, pancreatic cancer

Hospira Vincristine Sulphate 5 mg/5 mL Injection vial (preserved) Australia - English - Department of Health (Therapeutic Goods Administration)

hospira vincristine sulphate 5 mg/5 ml injection vial (preserved)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; mannitol; water for injections - vincristine sulphate injection is used in the treatment of cancers of the blood (eg. leukaemia or lymphomas), breast, head and neck or lung. it may be used to treat multiple myeloma (a cancer of plasma cells) and it may also be used in the treatment of some cancers in children. it may be used in a blood disorder known as idiopathic thrombocytopenic purpura (itp) after other treatments have not been successful. vincristine sulphate injection may be given alone or in combination with other anti-cancer medicines.

Hospira Gemcitabine Injection 38 mg/mL, 2 g/52.6 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine injection 38 mg/ml, 2 g/52.6 ml vial

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.